Case File
efta-01881229DOJ Data Set 10OtherEFTA01881229
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01881229
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
To:
Richard Merkin
Fran:
Jeffrey Epstein
Sent
Fri 5/18/2012 10:12:32 PM
Subject Re:
what do you mean by the " team".. the idea sounds,great. why convertible preferred. , what are
your concerns? . revenude model seems clear, . payor, providers, and insurance co . isnt that
right?, the start up salaries get paid from the old invesment as well as the new., there is still 4
million in cash, another 6 millin financing commited in response to milestones? of course they
have been paid, . yidong. team is supposed to be pretty strong., including. former goct officials (
real insurance).
On Fri, May 18, 2012 at 3:30 PM, Richard Merkin ote:
Your thoughts? This is not to be venture capital . Convertible preferred? If a loan ,.sinking
fund ? . are there receivables? Cross collateralizing on other assets? No clue. where is the
revenue coming from ? When? How does the team get paid? How have they been paid? What
happens if Yidong leaves? .
On May 18, 2012, at 5:31 AM, "Jeffrey Epstein" <[email protected]> wrote:
not sure what you mean by security, . examples? ?
On Fri, May 18, 2012 at 7:23 AM, Richard Merkin wrote:
How are you? Where are you? I am to play in am .will see how I do .Am
simultaneously at a healthcare conference ....multitasking! Re david sure
...need some security to protect downside .ideas?
On May 17, 2012, at 9:25 PM, "Jeffrey" [email protected]> wrote:
> David stem? Do you want my help? Bill tennis ? Careful of your health
>
> Sorry for all the typos .Sent from my iPhone
The information contained in this communication is confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
EFTA_R 1_00294008
EFTA01881229
communication in error, please notify us immediately by return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved
The information contained in this communication is confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
E FTA_R 1_00294009
EFTA01881230
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.